[Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein].
TNF is a central cytokine in the pathogenesis of rheumatoid arthritis(RA), which induces synovitis as well as joint damage. Etanercept is a recombinant human soluble TNF receptor that binds specifically to TNF receptor, and inhibits TNF receptor-mediated signaling cascade. Recent investigations have revealed successful clinical efficacy of biologics in RA including etanercept. We reviewed here the structure and efficacy of etanercept in RA according to the published evidence.
Fujikawa
Keita
K
Unit of Translational Medicine, Department of Immunology and Rheumatology, Graduate School of Biomedical Sciences, Nagasaki University.
Kawakami
Atsushi
A
Eguchi
Katsumi
K
D018501:Antirheumatic Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology; D002986:Clinical Trials as Topic; D000068800:Etanercept; D019317:Evidence-Based Medicine; D006801:Humans; D007074:Immunoglobulin G / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000502:physiology / Q000627:therapeutic use
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept